relugolix, estradiol, and norethindrone acetate

Details

Key Milestones2
Call for patient/clinician input openDecember 16, 2024
Call for patient/clinician input closedFebruary 18, 2025
Submission receivedFebruary 04, 2025
Submission acceptedFebruary 19, 2025
Review initiatedFebruary 20, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 08, 2025
Deadline for sponsors commentsMay 20, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 13, 2025
Expert committee meeting (initial)June 25, 2025
Draft recommendation issued to sponsorJuly 08, 2025
To
July 10, 2025
Draft recommendation posted for stakeholder feedbackJuly 17, 2025
End of feedback periodJuly 31, 2025